Singapore’s oncology landscape to advance with histotripsy technology

The approach is an ultrasound-based technique that offers a pain-free alternative.

Singapore’s oncology field is set for a significant transformation with the introduction of non-invasive, ultrasound-based histotripsy technology, strengthening its position in global cancer research and innovation, according to GlobalData.

The development follows Li Ka Shing Foundation’s and Temasek Trust’s $9.2m (S$12m) commitment to introduce the first-ever histotripsy tumor clinical trials to Southeast Asia.

The funding equips the National Cancer Centre Singapore and the National University Cancer Institute, Singapore with one histotripsy system each, supporting clinical trials involving 40 patients with liver, kidney, or pancreatic cancers.

Histotripsy is a non-invasive therapeutic technique that uses focused ultrasound, offering a pain-free, bloodless, and incision-free alternative.

The technology addresses challenges associated with traditional therapies, thereby broadening the spectrum of treatment for patients with untreatable tumours, said Jyoti Sharma, Medical Devices Analyst at GlobalData.

“By leveraging advanced technology and fostering cross-sector collaboration, Singapore not only enhances the treatment options available to its local patients but also establishes itself as a regional leader in medical research and innovation,” Sharma added.

S$1 = $0.77